Trial Profile
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Topotecan (Primary) ; Trilaciclib (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Proof of concept; Registrational
- Sponsors G1 Therapeutics
- 24 Oct 2023 Results assessing the occurrence of chemotherapy-induced myelosuppression events with standard of care chemotherapies for relapsed SCLC and supportive care interventions from NCT02454972, NCT02514447 and NCT02566993, presented at the 48th European Society for Medical Oncology Congress.
- 16 Jul 2022 Results from NCT02514447 and other studies investigating the pharmacokinetic drug-drug interaction potential of trilaciclib, published in the Clinical Drug Investigation
- 02 Jun 2022 Results from a post-hoc analysis of (NCT02499770 , NCT03041311 , NCT02514447 ) were presented in a poster at the 2022 American Society of Clinical Oncology (ASCO) annual meeting